PPT-Updated 2011 WHO Rubella Vaccine Position Paper and Implications for Regions and Countries

10 th Measles Initiative Meeting September 1314 2011 Washington DC Susan E Reef CDCGIDDEEB Peter M Strebel WHOHQIVBEPI Outline Global and regional status CRS burden Vaccine uptake and regional goals. Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . 11. th. Annual Meeting . Measles and Rubella Initiative. Washington, DC. Peter Strebel, WHO/EPI. The mission of the Decade of Vaccines is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.". 11. th. Annual Meeting . Measles and Rubella Initiative. Washington, DC. Peter Strebel, WHO/EPI. The mission of the Decade of Vaccines is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.". Regional MR TAG . Nairobi, Kenya . June 2-3 , 2015 . Outline . Background . Epidemiology of Rubella . Strategic options for rubella control AFR . MR introduction progress noted issues related to MR introduction in AFR . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Dr. Khin Devi Aung. Gavi Secretariat. 21. . June 2016, Geneva. 1. #. vaccineswork. AGENDA. About Gavi, the Vaccine Alliance. Gavi’s. support to countries. Gavi’s. 2016-2020 Strategy. Gavi’s. Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Measles and Rubella Annual Partners Meeting, September 15-16 2015. Background. The MRI FRR is developed by the M&RI FRR/RMAWG. Country population data is drawn from UNDP estimates. Vaccine type and timing of SIAs is from countries . MMR2 coverage (%). Source: . Country reports through the PAHO-WHO/UNICEF Joint Reporting Forms (JRF), 2019.. *MMR: measles-mumps-rubella vaccine; **Measles-rubella (MR) vaccine.. in . Low. -Resource Settings: . Limitations. , Biases, and . Potential . for Strengthening. Amy Winter, PhD Candidate, Princeton University. Advisor:. Jess Metcalf. Assistant Professor of Ecology and . easily through the air, or through contact with uids in the nose or throat. The viruses can pass from person to person by coughing, sneezing, or sharing food or drinks. Children may become inf MEA R) VACCINE What is the measles, mump and rubella (MMR) vaccine? The MMR vaccine protects against three diseases: measles, mumps and rubella (german measles). The vaccine is approved by He alth C Opening Comments & Perspectives. Dr. Suresh Jadhav. Executive Director. Serum Institute of India Pvt. Ltd.,. ssj@seruminstitute.com. . We, at Serum Institute of India Pvt. Ltd., feel proud of being a partner to PAHO / WHO in achieving what is designated to be a historical achievement in eradication of Measles & Rubella diseases from the Americas.. .. Education Department.. Kolkata. . Measles . - . An acute viral infection spread via respiratory secretions or aerosols. leading causes of death . among young children . even though a safe and cost-effective vaccine is available.